Many questions about the heparin allergy outbreak remain unanswered. Does the heparin allergy originate from a single plant reflecting a quality problem? The implicated lots of heparin appear to ...

The story of a grad student who overcame remarkable odds only to be denied his moment of glory, or a tale of dark deceit and devilish doings? The story of heparin is as complicated as the chemistry ...

Taurolidine is an antibacterial and antifungal agent with a mechanism of action that is less prone to development of antimicrobial resistance. A taurolidine/heparin lock solution carries a lower risk ...

We evaluated two patients in whom heparin-induced thrombocytopenia developed after orthopedic surgery, with the delayed-onset type in Patient 1 and the spontaneous type in Patient 2 (Figure 1). The ...

If the heparin shortage goes critical, there are some steps that could mitigate the harm, as one group outlined. "Manufacturing disturbances and an outbreak of African swine fever in China are ...

We read with concern the analysis by Davidson et al. (Sept. 26 issue). 1 They use the pooled placebo groups from two sepsis trials, divided into two groups — patients who either were receiving heparin ...

ON NOV. 19, 2007, St. Louis Children's Hospital noticed the first of several acute allergic reactions in children undergoing dialysis. The hospital reported the reactions to the Missouri Department of ...

UFH is a mixture of glycosaminoglycans of varying lengths (mean 15,000 daltons; range 3000-30,000 daltons). This heterogeneity results in variable anticoagulant activity and pharmacokinetics. In fact, ...

Researchers moved one step closer to the ability to make heparin in cultured cells. Heparin is a potent anti-coagulant and the most prescribed drug in hospitals, yet cell-culture-based production of ...

Pharmaceutical-grade heparin is derived from the mucosal tissue of animals that have been slaughtered for meat such as pigs and cattle. Research conducted between 2003 and 2008 eventually led to the ...

Investing.com -- Laboratorios Farmaceuticos Rovi SA (BME:ROVI) reduced its full-year 2026 revenue guidance on Wednesday, citing decreased demand from a global pharmaceutical company agreement and ...